Insulet Corporation $PODD Shares Sold by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. trimmed its holdings in shares of Insulet Corporation (NASDAQ:PODD – Free Report) by 73.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,818 shares of the medical instruments supplier’s stock after selling 35,598 shares during the period. Jefferies Financial Group Inc.’s holdings in Insulet were worth $1,672,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the stock. BlackRock Inc. acquired a new position in Insulet during the 2nd quarter worth $1,018,582,000. Arrowstreet Capital Limited Partnership boosted its stake in Insulet by 462.7% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock worth $258,088,000 after acquiring an additional 1,011,369 shares during the last quarter. Amundi grew its holdings in shares of Insulet by 14.4% in the 1st quarter. Amundi now owns 446,918 shares of the medical instruments supplier’s stock valued at $93,781,000 after buying an additional 56,225 shares during the period. Renaissance Technologies LLC grew its stake in Insulet by 40.5% in the first quarter. Renaissance Technologies LLC now owns 426,003 shares of the medical instruments supplier’s stock valued at $89,392,000 after acquiring an additional 122,720 shares during the period. Finally, Man Group plc acquired a new position in shares of Insulet in the 2nd quarter valued at approximately $78,746,000.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $152.48 on Monday. Insulet Corporation has a one year low of $126.40 and a one year high of $354.88. The company has a market cap of $10.58 billion, a price-to-earnings ratio of 24.83, a PEG ratio of 1.16 and a beta of 1.06. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.51 and a quick ratio of 1.83. The firm has a 50 day simple moving average of $142.14 and a 200 day simple moving average of $173.54.

Insulet (NASDAQ:PODD – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share for the quarter, beating the consensus estimate of $1.59 by $0.40. Insulet had a return on equity of 31.76% and a net margin of 13.44%. The company had revenue of $842.00 million for the quarter, compared to the consensus estimate of $832.63 million. During the same quarter last year, the business posted $1.24 EPS. Insulet’s revenue for the quarter was up 19.2% on a year-over-year basis. Research analysts predict that Insulet Corporation will post 6.76 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on PODD shares. TD Cowen reissued a “hold” rating on shares of Insulet in a research note on Wednesday, November 4th. Wells Fargo & Company raised their target price on shares of Insulet from $144.00 to $172.00 and gave the company an “equal weight” rating in a research note on Thursday, November 5th. Wall Street Zen raised shares of Insulet from a “hold” rating to a “buy” rating in a research report on Saturday, November 7th. UBS Group boosted their price objective on Insulet from $150.00 to $171.00 and gave the stock a “neutral” rating in a report on Thursday, November 5th. Finally, Barclays upped their price target on shares of Insulet from $150.00 to $165.00 and gave the company an “equal weight” rating in a research note on Friday, November 6th. Twelve research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $185.67.

Check Out Our Latest Report on Insulet

About Insulet

(Free Report)

Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps. Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.

Recommended Stories

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.